Please assess the completion status of the following clinical trial:

Trial Title: A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent~2. Women of child-bearing potential must have a negative pregnancy test~Multiple Myeloma:~Confirmed diagnosis of Multiple Myeloma with measurable disease, having been treated with at least two prior lines of therapy.~Lymphoma:~Confirmed diagnosis of Non-Hodgkin Lymphoma with measurable disease, having been treated with at least one anthracycline-based therapy, with relapse or progression since the last treatment received.~Exclusion Criteria:~1. Any of the following treatments, within the specified time frame, prior to the first dose of TAS4464:~   1. Major surgery within 28 days~  2. Radiation/chemotherapy within 21 days~  3. Monoclonal antibodies within 28 days~  4. Corticosteroid administration \>20 mg/day of prednisone or equivalent within 14 days~  5. Proteasome inhibitors within 14 days~  6. Immunomodulatory agents within 7 days~  7. Stem cell transplant within 3 months~  8. Current immunosuppressive treatment for graft versus host disease~  9. Current use of an investigational agent~2. Active graft versus host disease~3. Known serious illness or medical condition~4. Prior treatment with TAS4464 or known hypersensitivity to any of its inactive ingredients or drugs similar in class~5. Pregnant or breast-feeding female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS4464 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).